U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill ...

EST Vertex Pharmaceuticals (VRTX)’ non-opioid painkiller approved by FDA, Bloomberg saysInvest with Confidence: Follow TipRanks' Top Wall ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Vertex (VERX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...

In December, Vertex's CASGEVY gained regulatory approval in the UAE for sickle cell disease and transfusion-dependent beta-thalassemia. Suzetrigine for moderate-to-severe acute pain awaits an FDA ...